title: High Expression of BCCIP β Can Promote Proliferation of Esophageal Squamous Cell Carcinoma.
abstract: BCCIP was originally identified as a BRCA2 interacting protein in humans and Ustilago maydis. It had low expression in some human cancer tissues. However, recent research indicated that many caretaker genes are also necessary for cell viability and their expression could contribute to tumor progression.
  
  
  
  To characterize whether BCCIP is a caretaker gene in esophageal squamous cell carcinoma (ESCC).
  
  
  
  Western blotting and immunohistochemistry were used to measure the expression of BCCIP β. In vitro studies were used to verify the effects of BCCIP β in Eca109 cells.
  
  
  
  Expression of BCCIP β was notably higher in tumor tissues of ESCC and Eca 109 cells. Meanwhile, the immunohistochemistry stain revealed that BCCIP β was positively correlated with clinical pathologic variables such as tumor size and tumor grade, as well as Ki-67, and prompted poor prognosis. In vitro studies such as starvation and refeeding assay along with BCCIP β-shRNA transfection assay demonstrated that BCCIP β expression promoted proliferation of ESCC cells. In addition, BCCIP β downregulation by silencing RNA significantly decreased the rate of colony formation, alleviated cellular apoptosis and increased the chemosensitivity of cisplatin.
  
  
  
  This research first put forward that BCCIP β is an oncogene in human ESCC and contributes to the poor outcome of the deadly disease.
authors.affiliation: Department of Gastroenterology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China.
authors.forename: Lingling
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China.
authors.forename: Sujie
authors.initials: S
authors.lastname: Ni
authors.affiliation: Department of Medical Oncology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China.
authors.forename: Chaoyan
authors.initials: C
authors.lastname: Shen
authors.affiliation: Department of Gastroenterology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China.
authors.forename: Zhipeng
authors.initials: Z
authors.lastname: Lin
authors.affiliation: Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Ouyang
authors.affiliation: Department of Radiology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Xia
authors.affiliation: Department of Medical Oncology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China.
authors.forename: Li
authors.initials: L
authors.lastname: Liang
authors.affiliation: Department of Medical Oncology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China.
authors.forename: Wenyan
authors.initials: W
authors.lastname: Jiang
authors.affiliation: Department of Gastroenterology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China. nrz0513@sina.cn.
authors.forename: Runzhou
authors.initials: R
authors.lastname: Ni
authors.affiliation: Department of Pathology, Affiliated Hospital of Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu, China. zhjg226@sina.com.
authors.forename: Jianguo
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents; D017209:Apoptosis / Q000235:genetics*; D015153:Blotting, Western; D002135:Calcium-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018797:Cell Cycle Proteins / Q000235:genetics* / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000235:genetics*; D002945:Cisplatin; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D055785:Gene Knockdown Techniques; D006801:Humans; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009687:Nuclear Proteins / Q000235:genetics* / Q000378:metabolism; D011379:Prognosis; D034741:RNA, Small Interfering; D047368:Tumor Burden; D014410:Tumor Stem Cell Assay
chemical_list: D000970:Antineoplastic Agents; C415366:BCCIP protein, human; D002135:Calcium-Binding Proteins; D018797:Cell Cycle Proteins; D009687:Nuclear Proteins; D034741:RNA, Small Interfering; D002945:Cisplatin
keywords: BCCIP β; Eca109; Esophageal squamous cell carcinoma; Proliferation